AR041125A1 - Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende - Google Patents

Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende

Info

Publication number
AR041125A1
AR041125A1 ARP030103176A ARP030103176A AR041125A1 AR 041125 A1 AR041125 A1 AR 041125A1 AR P030103176 A ARP030103176 A AR P030103176A AR P030103176 A ARP030103176 A AR P030103176A AR 041125 A1 AR041125 A1 AR 041125A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
cycloalkyl
heteroaryl
heterocycloalkyl
Prior art date
Application number
ARP030103176A
Other languages
English (en)
Spanish (es)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR041125A1 publication Critical patent/AR041125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP030103176A 2002-09-12 2003-09-02 Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende AR041125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12

Publications (1)

Publication Number Publication Date
AR041125A1 true AR041125A1 (es) 2005-05-04

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103176A AR041125A1 (es) 2002-09-12 2003-09-02 Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende

Country Status (10)

Country Link
US (1) US20040116444A1 (cg-RX-API-DMAC10.html)
EP (1) EP1539736A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006506350A (cg-RX-API-DMAC10.html)
AR (1) AR041125A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003269949A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314139A (cg-RX-API-DMAC10.html)
CA (1) CA2494975A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05002418A (cg-RX-API-DMAC10.html)
TW (1) TW200503717A (cg-RX-API-DMAC10.html)
WO (1) WO2004024719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine

Also Published As

Publication number Publication date
US20040116444A1 (en) 2004-06-17
TW200503717A (en) 2005-02-01
MXPA05002418A (es) 2005-05-27
BR0314139A (pt) 2005-07-12
CA2494975A1 (en) 2004-03-25
AU2003269949A1 (en) 2004-04-30
WO2004024719A1 (en) 2004-03-25
JP2006506350A (ja) 2006-02-23
EP1539736A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR035532A1 (es) Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
AR041508A1 (es) Compuestos con actividad en los receptores de glutamato metabotropicos
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
AR016666A1 (es) Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene
AR035260A1 (es) Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
AR037355A1 (es) Compuesto derivado de difenilamina, composicion farmaceutica y su uso en la fabricacion de medicamentos
AR035695A1 (es) Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
AR033306A1 (es) Compuestos
AR045582A1 (es) Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
DK0447285T3 (da) Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
AR038882A1 (es) Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene
PE20030269A1 (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas
CO5011090A1 (es) Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.

Legal Events

Date Code Title Description
FB Suspension of granting procedure